TORI 104 Pre-Surgical Dasatinib

Inclusion Criteria:

• Informed signed consent, female, over 18 years of age nad Karnofsky performance status index greater than 80%.
• Histologically proven invasive breast cancer through either core needle biopsy or an incisional biopsy. Excisional biopsy not allowed.
• Tumor must be confined to either the breast or to the breast and ipsilateral axilla. Tumor size of greater than 2cm (T1 with T=2m, T2-T3. Patient can have clinically positive (N1) or clinically negative)
• Neutrophils greater than 1.5 x 109/L, Platelets greater tahn 100 x 109/L, Hemoglobin greater than 10g/dL.
• Total bilirubin less than 1 UNL, AST and ALT less than 2.5 UNL, Alk phos less than 5 UNL, creatinine less than 175umol/L (2mg/dL)
• not more than 28 days from the time of the initial diagnosis and 8 days from registration to the first dose of dasatinib shall elapse.
• Patients must be accessible for treatment and the 30-day follow-up and compliant with study procedures.
• Negative pregnancy test within 7 days prior to registration for women of childbearing potential.

Exclusion Criteria:

• Prior or concurrent systemic anticancer therapy
• Prior or concurrent ipsilateral radiation therapy for invasive or noninvasive breast cancer.
• Pregnant or lactating patients. Patients of childbearing potential must implement adequate non-hormonal contraceptive measures during study treatment.
• Any T1 (with exception of T1 with T=2cm) or T4 or N2 or known N3 or M1 breast cancer.
• Concurrent or congestive heart failure, unstable angina pectoris or MI in past 6 months; uncontrolled hypertension or high risk uncontrolled arrhythmias; any history of significant ventricular arrhythmia.
• History of significant neurological or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding of informed consent; active uncontrolled infection.
• Past or prior history of neoplasm other than breast carcinoma, except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix or other cancer curatively treated.
• Concurrent treatment with ovarian hormonal replacement therapy. Prior treatment should be stopped at least 2 weeks prior to registration.
• Concurrent treatment with other experimental drugs or treatment wih investigational drugs with 30 days of registration.
• Prior hormonal therapy with any hormonal agents such as ralozifene, Tamoxifen or other selective estrogen receptor modulators (SERMs), either for osteoporosis or prevention.